TP53 and neuroblastoma: Interestingly, TP53 remained unchanged in response to the treatment, which was consistent to the previous study reported that OXY moderated p53-independent S phase arrest, ROS–independent apoptosis in neuroblastoma cells (Rahman et al., 2017).